Morphoproteomic Profiling of the Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Desmoplastic Small Round Cell Tumor (EWS/WT1), Ewing's Sarcoma (EWS/FLI1) and Wilms' Tumor(WT1)

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Subbiah, Vivek ^a   Brown, Robert E ^b   Jiang, Yunyun ^a   Buryanek, Jamie ^b   Hayes Jordan, Andrea ^a   Kurzrock, Razelle ^a,c   Anderson, Pete M ^d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d Levine Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; S6 KINASE; SERINE;

ADOLESCENT; ADULT; ARTICLE; CASE REPORT; CELL MEMBRANE; CYTOPLASM; DESMOPLASTIC SMALL ROUND CELL TUMOR; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EWING SARCOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MORPHOPROTEOMICS; NEPHROBLASTOMA; PILOT STUDY; PROTEIN EXPRESSION; PROTEOMICS; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84880774563     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068985     Document Type: Article

References (22)

1. Kushner BH, LaQuaglia MP, Wollner N, Meyers PA, Lindsley KL, et al. (1996) Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J Clin Oncol 14: 1526-1531.
2. Lal DR, Su WT, Wolden SL, Loh KC, Modak S, et al. (2005) Results of multimodal treatment for desmoplastic small round cell tumors. J Pediatr Surg 40: 251-255.
3. Naing A, Kurzrock R, Burger A, Gupta S, Lei X, et al. (2011) Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res 17: 6052-6060.
4. Merchant SA, Badhe PB, (1995) Nephroblastomatosis-pathologic and imaging characteristics. J Postgrad Med 41: 72-80.
5. Institute NC (2012) Wilm's Tumor and Other Childhood Kidney Tumors Treatment.
6. Davidoff AM, (2009) Wilms' tumor. Curr Opin Pediatr 21: 357-364.
7. Sawyer JR, Tryka AF, Lewis JM, (1992) A novel reciprocal chromosome translocation t(11;22)(p13;q12) in an intraabdominal desmoplastic small round-cell tumor. Am J Surg Pathol 16: 411-416.
8. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, et al. (1992) Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359: 162-165.
9. Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, et al. (1994) A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 6: 146-151.
10. Jeon IS, Davis JN, Braun BS, Sublett JE, Roussel MF, et al. (1995) A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene 10: 1229-1234.
11. Huff V, (1998) Wilms tumor genetics. Am J Med Genet 79: 260-267.
12. Maiti S, Alam R, Amos CI, Huff V, (2000) Frequent association of beta-catenin and WT1 mutations in Wilms tumors. Cancer Res 60: 6288-6292.
13. Subbiah V, Naing A, Brown RE, Chen H, Doyle L, et al. (2011) Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. PLoS One 6: e18424.
14. Stone AA, Chambers TC, (2000) Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. Exp Cell Res 254: 110-119.
15. Rosner M, Hengstschlager M, (2008) Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. Hum Mol Genet 17: 2934-2948.
16. Rosner M, Siegel N, Valli A, Fuchs C, Hengstschlager M, (2010) mTOR phosphorylated at S2448 binds to raptor and rictor. Amino Acids 38: 223-228.
17. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM, (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
18. Toschi A, Lee E, Xu L, Garcia A, Gadir N, et al. (2009) Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol 29: 1411-1420.
19. Murphy AJ, Viero S, Ho M, Thorner PS, (2009) Diagnostic utility of nestin expression in pediatric tumors in the region of the kidney. Appl Immunohistochem Mol Morphol 17: 517-523.
20. Zakikhani M, Blouin MJ, Piura E, Pollak MN, (2010) Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 123: 271-279.
21. Barber-Rotenberg JS, Selvanathan SP, Kong Y, Erkizan HV, Snyder TM, et al. (2012) Single Enantiomer of YK-4-279 Demonstrates Specificity in Targeting the Oncogene EWS-FLI1. Oncotarget 3: 172-182.
22. Vincent TS, Hazen-Martin DJ, Garvin AJ, (1996) Inhibition of insulin like growth factor II autocrine growth of Wilms' tumor by suramin in vitro and in vivo. Cancer Lett 103: 49-56.